Stockscreener 앱 받기
2.22
3.26%
0.07
시간 외 거래:
2.20
-0.02
-0.90%
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene Therapeutics (NASDAQ:ALLO) SVP Sells $11,942.45 in Stock - MarketBeat
David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock - MarketBeat
Allogene (NASDAQ: ALLO) SVP share sale funds tax withholding - Stock Titan
Allogene (ALLO) CEO executes 47,763-share tax sell-to-cover transaction - Stock Titan
Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329 - Traders Union
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 5.1%Time to Sell? - MarketBeat
Allogene targets pivotal ALPHA3 data in April and extends cash runway into 2028 while prioritizing scalable CAR T programs - MSN
Take the Zacks approach to beat the markets: Starbucks, Amgen, Allogene in focus - MSN
Allogene Therapeutics (NASDAQ: ALLO) proposes sale of 4,835 shares - Stock Titan
Citizens reiterates Allogene stock rating on pipeline progress - Investing.com
Citizens reiterates Allogene stock rating on pipeline progress By Investing.com - Investing.com UK
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expands By 19.8% - MarketBeat
Allogene Therapeutics Banks on 2026 Trial Catalysts - The Globe and Mail
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
Analysts Are Bullish on Top Healthcare Stocks: Equillium (EQ), Qiagen (QGEN) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail
Canaccord Genuity Group Reiterates Buy Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - AOL.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - The Globe and Mail
El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Benzinga
Allogene Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Q32 Bio (QTTB) - The Globe and Mail
Allogene Therapeutics (ALLO) Projects Key Milestones for 2026 - GuruFocus
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - Sahm
Allogene Therapeutics 2025 Annual Report: Advancing Allogeneic CAR T Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlight - GuruFocus
Allogene Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast By Investing.com - Investing.com India
Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast - Investing.com South Africa
Allogene (ALLO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Rate Cut: Will Allogene Therapeutics Inc benefit from geopolitical trends2026 Drop Watch & Weekly Momentum Picks - baoquankhu1.vn
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q4 Loss, Highlights Key 2026 Clinical Catalysts - ChartMill
Allogene Therapeutics (NASDAQ:ALLO) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
ALLOGENE THERAPEUTICS ($ALLO) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Allogene Therapeutics Q4 net loss narrows - TradingView
Allogene Therapeutics: Fourth Quarter Earnings Overview - Bitget
Allogene Therapeutics: Q4 Earnings Snapshot - Barchart
Allogene Therapeutics 2025 10-K: Net loss $190.9M, EPS $(0.87); runway into Q1 2028 - TradingView
Allogene Therapeutics (NASDAQ: ALLO) outlines allogeneic CAR T plans and risks - Stock Titan
Allogene (NASDAQ: ALLO) details 2025 loss, pipeline data milestones and cash runway - Stock Titan
Cancer and autoimmune push: inside Allogene’s 2026 CAR T trials - Stock Titan
Allogene Therapeutics advances ALLO-329 using Dagger technology to target autoimmune disease - Traders Union
Aug Shorts: What are the future prospects of Allogene Therapeutics IncAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
Allogene Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - AOL.com
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 7.4%Here's Why - MarketBeat
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus - TradingView
Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN
Allogene Therapeutics (ALLO) Expected to Announce Earnings on Thursday - MarketBeat
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,132 Shares of Stock - MarketBeat
Allogene (ALLO) SVP executes 7,132-share tax sell-to-cover trade - Stock Titan
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen - Yahoo Finance
1.20%
0.06%
자본화:
|
볼륨(24시간):